oncologY 2012 · Manual of Cancer Treatment Recovery presents the first comprehensive program to guide the recovery from cancer and its treatment. ... healing right from the start,

PRSR

T ST

DU

.S. P

osta

gePA

IDM

inne

apol

is, M

NPe

rmit

No.

294

18

Dem

os M

edic

al

Publ

ishi

ng11

Wes

t 42n

d St

reet

New

Yor

k, N

Y 10

036

SAv

e 15

%

Plu

S Fr

ee S

hIP

PIn

g

Wh

eN Y

oU

oRD

eR o

Nli

Ne

bY S

ePTe

Mbe

R 30

, 201

2*

oN

oRD

eRS

ove

R $2

9.00

www.demosmedpub.com

viSiT AMAzon, bn.coM aND google bookS To fiND

DeMoS MeDIcAl TiTleS iN a vaRieTY of e-book foRMaTS.

SAve 15% PluS Free ShIPPIng

WheN YoU oRDeR oNliNe bY SePTeMbeR 30, 2012*

oN oRDeRS oveR $29.00

Visi

t Am

azon

, bn.

com

and

Goo

gle

Book

s to

find

Dem

os M

edic

al ti

tles

in a

var

iety

of e

-boo

k fo

rmat

s.DeMoS MeDical PUbliShiNg

oncologY 2012

DEM OS M EDIC AL PU BLISHI NG | oN cologY | 2012

fRee ShiPPiNg* WHEN YOU ORDER ONLINE *oN oRDeRS oveR $29.00


To oRDeR viSiT www.demosmedpub.com oR call 1-800-532-8663

43

neW AnD ForThcoMIng TITleS 2012

The Must-Know Points of Medical Oncology Distilled into a Single Source for Targeted Board Review, Self- assessment or Handy Quick Reference

oncology boards Flash reviewFrancis P. Worden, MD, Associate Professor of Internal Medicine, Director, Division of Hematology/Oncology Fellow-ship Program, University of Michigan Medical School

Coverage extends across the range of major hematologic ma-lignancies and solid tumors, as well as reviews of pharmacol-ogy, biostatistics, genetics and tumor biology, and survivor-ship and palliative care. Each topic is consistently presented with the key points summarized in bullet point form for easy recall. Question-based headings enable the reader to systematically review and assess his knowledge. This study guide covers all the basic points of medical oncology that you must know.

ONCOLOGY BOARDS FLASH REVIEW FEATURES:

r Must-know points of medical oncology

r Coverage of hematologic malignancies, solid tumors, pharmacology, biostatistics, genetics and tumor biology, and survivorship and palliative care

r Key points summarized in bullet form for easy recall

r Useful tools for board review, self-assessment or handy quick reference

conTenTS: Hematologic Malignancies; Acute Leukemias; Myelodysplastic Syndromes; CML and Myelo-proliferative Disorders; Hodgkin’s Disease; Multiple Myeloma and Plasma Cell Dyscrasia; Non Hodgkin’s Lymphoma; Non Hodgkin’s Lymphoma; CLL; Aerodigestive Malignancies; Non small cell lung cancers; Small cell lung cancer; Mesothelioma; Thymic carcinoma; Head and Neck cancers and salivary gland tumors; Endocrine Malignancies; Thyroid cancers; Adrenocortical carcinoma and Pheochromocytomas; Breast Cancer; Breast cancer; Genitourinary Malignancies; Bladder cancer; Germ cell tumors; Prostate cancer; Renal cell carcinoma; GI Malignancies; Gallbladder and biliary tree malignancies; Colorectal cancers; Anal cancer; Esophageal cancer; Gastric cancer; Pancreatic cancer; Hepatocellular carcinoma; Neuroendocrine tumors; Sarcoma; Soft tissue sarcomas and desmoid tumors; CNS Malignancies; Cancers of Unknown Primary; Pharmacology; Pharmacology of cancer drugs and agents; Biostatistics; Genetics and Tumor Biology; Supportive Care/Palliative Care; Melanoma; Gyn Malignancies

December 2012 • 256 pp. • Softcover • 978-1-936287-81-9 • E-book ISBN 978-1-617051-30-2 • $45.00/$38.25

A Comprehensive Learning and Self-Assessment Tool

radiation oncology Self-Assessment guideEdited by John Suh, MD, Professor and Chairman, Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio

Organized by site, Radiation Oncology Self-Assess-ment Guide covers in detail all the sites and cancer types currently treated with radiotherapy. Detailed questions, organized in a “flash-card” format are included on the natural history, epidemiology, diagnosis, staging, treatment options and treatment-related side effects for each cancer type allow the reader to thoroughly assess his knowledge of the field and identify strengths as well as as areas need further study and preparation. The dis-cussion of the questions includes key literature citations reinforcing the reader’s knowledge of critical studies and guidelines in the field. Written in joint collaboration by residents and staff radiation oncologists at the Depart-ment of Radiation Oncology at the Cleveland Clinic Taussig Cancer Institute, the book contains more than 900 questions addressing the full gamut of the science and art of radiation oncology today.

RADIATION ONCOLOGY SELF- ASSESSMENT GUIDE FEATURES: r Comprehensive coverage of radiation oncology

r “Flash-Card” format facilitates recall of key data, treatment assessment and patient management, and important original studies; all covered in the question sets

r Chapter authors are from the Cleveland Clinic

conTenTS: 1. Head and Neck Cancers, 2. Central Nervous System, 3. Breast Cancers, 4. Lung Cancer, 5. Gas-trointestinal Cancers, 6. Genitourinary Cancers, 7. Gynecologic Cancers, 8. Lymphomas, 9. Pediatric Cancers

September 2012 • 512 pp. • Softcover • 978-1-936287-53-6 E-book ISBN 978-1-617050-98-5 • $75.00/$63.75


Francis P. Worden

Oncology Boards Flash Review

ForThcoMIng

neW

4

Gen

eral

Que

stio

ns •

Ans

wer

sHe

ad a

nd n

eck

canc

ers

Answer 5The addition of docetaxel (T) to the PF backbone was investigated in two phase III randomized studies and demonstrated improved LRC and OS (not DM), compared to PF alone. In the Vermorken study, pts were treated with TPF X 4 cycles followed by RT alone. In the Posner trial, pts were treated with similar induction chemotherapy (3 cycles) followed by RT + concurrent weekly carboplatin.

Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–578.

Answer 6400 mg/m2 loading dose 1 week prior to RT and 250 mg/m2 weekly during RT. It was tested in a phase III study compared to RT alone and demonstrated superior outcomes, including 2 yr LRC (50% vs 41%) and 3 yr OS (55% vs 45%). There was no difference in rates of DM (16% vs 17%). 5 yr results confirmed these findings.

Answer 7In these procedures the following is removed:

Radical neck dissection (RND) – removes levels I–V, sternocleidomastoid muscle (SCM), omohyoid muscle, IJV, EJV, CN XI, submandibular gland.Modified RND – removes levels I–V, but does not remove at least one of the following structures: SCM, IJV or CN XI.Selective neck dissection – does not remove all of levels I–V. There are several named subtypes of selective neck dissections, including:

supraomohyoid neck dissection – removes levels I–III.lateral neck dissection – removes levels II–IV.

Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357:1705–1715.

Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357:1695–1704.

Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21:92–98.

Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1798–1804.

Pignon JP, le Maître A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;2:4–14.

Answer 4Chemotherapy is indicated in stage III/IV disease based on several prospective randomized trials that demonstrated LRC, DFS and OS advantages with the addition of concurrent chemotherapy. This benefit was seen compared to standard fractionated RT (Adelstein) as well as hyperfractionated RT (Brizel). The MACH-NC meta-analysis also demonstrated a 4% 5 yr OS advantage overall, with the highest advantage seen in the setting of concurrent chemotherapy (35% vs 27%).

Frank, DK, Sessions RB. Management of the neck – surgery. In: Harrison LB, Sessions RB, Hong WK, eds. Head and Neck Cancer: A Multidisciplinary Approach. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:185–189.

Suh_xxxxx_R2_CH01_07-11-12_1-50.indd 4 11/07/12 10:20 PM

DEM OS M EDIC AL PU BLISHI NG | oN cologY | 2012DEM OS M EDIC AL PU BLISHI NG | oN cologY | 2012

65

To oRDeR viSiT www.demosmedpub.com oR call 1-800-532-8663fRee ShiPPiNg* WHEN YOU ORDER ONLINE *oN oRDeRS oveR $29.00

Manual of cancer Treatment recoveryWhat the Practitioner Needs to Know and DoStewart Fleishman, MD, Former Director of Cancer Supportive Services at the Continuum Cancer Centers of New York and the Associate Chief Medical Officer of Continuum Hospice Care-Jacob Perlow Hospice

Manual of Cancer Treatment Recovery presents the first comprehensive program to guide the recovery from cancer and its treatment. The Manual helps you, other practitioners, and your staff members plan early intervention and promote healing right from the start, before distressing symptoms begin. Manual of Cancer Treatment Recovery teaches how to guide patients and families in setting up a simple plan that minimizes treatment’s unwanted effects, how to coordinate with other clinicians involved in the patient’s management; and how to develop a directed survivorship program in your practice. Divided into three sections, the book covers what everyone needs to know about survivorship, how to implement effective and enduring care, and how to work with patients utilizing The LEARN System (Living, Education, Activity, Rest, Nutrition) that Dr. Fleishman developed.

The book also includes easy-to-use forms that patients may complete even before the initial consultation and post-treatment survivorship care plans for primary care providers.

Whether used independently or in conjunction with Dr. Fleishman’s patient-focused companion book Learn to Live Through Cancer, the Manual of Cancer Treatment Recovery enables the oncology care team to anticipate patient and family needs even before they arise.

The Manual Will Help You To:

r Organize recovery plans during treatment to improve quality of life

r Develop an innovative system to minimize loss of vital energy, lean body mass, and distress before they happen

r Develop a survivorship program for your practice

r Coordinate oncology care with specialists and primary care providers

r Integrate end-of-life issues into the care trajectory

r Improve patient care during and after treatment

r Nurture your patients’ recovery preventively and systematically

conTenTS: Introduction: How to Use This Book and Why It Is Important to You, SECTION I: What You Need To Know About Survivorship: 1. Emerging Needs of Survivorship: Beyond The Institute of Medicine Report, From Cancer Patient to Cancer Survivor: Lost in Transition, 2. Early Intervention to

Improve Treatment Outcomes, SECTION II: Implementing Effective Survivorship Care In Practice: 3. Apply Survivorship Tools Early in Care, 4. Comorbidities and Cancer Survivorship, 5. Easing Communi-cation in Multiprovider Management, 6. Effectively Managing the Transitional Points in Care, SECTION III: Working With Your Patients: 7. Tools for Survivorship The LEARN System: Living, Education, Activity, Rest, Nutrition, 8. The LEARN System Components: Finding Meaning and Purpose to Sustain Oneself During Treatment (“Living”), 9. The LEARN System Components: Knowing About Cancer and Its Treatment Eases Uncertainty (“Education”), 10. The LEARN System Components: Maintaining Activity During Treatment Improves Outcomes (“Activity” and Exercise), 11. The LEARN System Components: Resting and Sleeping Effectively Furthers Recovery (“Rest” and Sleep), 12. The LEARN System Compo-nents: Maintaining Optimal Nutrition Eases Time in Treatment and Recovery (“Nutrition”), 13. Giving Forward, PATIENT AND FAMILY WORKSHEETS: What Is Important to Me, Family History Form, Important Revelations to My Treatment Team, Questions I Want Answered, My Weekly Recovery Planner: Using The LEARN System®, Distress Thermometer, <i>My Recovery Plan Communicator</i>: Breast Cancer, Prostate Cancer, Lung or Esophageal Cancer, Colon, Rectal, Stomach, or Pancreatic Cancer, Ovarian, Cervical, or Uterine Cancer, Head and Neck Cancer, Kidney or Bladder Cancer, Brain or Spinal Cord Cancer, Journal Page: Charting My Course, Enteral Nutrition (Tube Feeding), What I Am Supposed to Be Eating or Drinking When I Can’t Eat Anything, Trusted Internet Sites, Your Personal Health Record: General Template, PHR: Brain or Spinal Cord Cancer, PHR: Breast Cancer, PHR: Colorectal or Gastric Cancer, PHR: Gynecologic Cancer, PHR: Head and Neck Cancers, PHR: Hepatobiliary Cancer, PHR: Kidney or Bladder Cancer, PHR: Leukemia, PHR: Lung Cancer, PHR: Lymphomas, PHR: Myeloma, PHR: Pancre-atic Cancer, PHR: Prostate Cancer, Contents v PHR: Sarcoma, PHR: Testicular Cancer, PHR: Thymoma, My Personal Affairs, Journal Page: My Bucket List, Five Wishes

December 2011 • 256 pp. • Softcover • 978-1-936287-31-4 • E-book ISBN 978-1-617050-61-9 • $45.00/$38.25

An Easy-to-Read and Understand Guide for Cancer Patients and Their Families

learn to live Through cancerWhat You Need to Know and DoStewart Fleishman, MD, Former Director of Cancer Sup-portive Services at the Continuum Cancer Centers of New York and the Associate Chief Medical Officer of Continuum Hospice Care-Jacob Perlow Hospice

Learn to Live Through Cancer: What You Need to Know and Do presents a step-by-step guide to improve the length and quality of life for cancer survivors, helping them to manage the variety of physical, emotional, and spiritual issues they face proactively.

In Learn to Live Through Cancer: What You Need to Know and Do cancer survivors will learn how to evaluate their condition, improve their communication with healthcare providers, research their illness and treatment options, seek complementary therapies when necessary, improve overall health habits, tend to their emotional well-being, and continue to monitor the long-term success of their survivorship program.

The book is a complete guide to getting a person with cancer through that critical time from diagnosis to remission and on with their life. It is an inspirational, cutting-edge book that provides a roadmap to a healthier and meaningful future following a cancer diagnosis.

2011 • 360 pp. • Softcover • 978-1-936303-08-3 • E-book ISBN 9781617050626 • $18.95/$16.15

“…Addresses the important issues of survivorship, with an emphasis on starting recovery right from the initial diagnosis. Several helpful worksheets for pa-tients help them focus on what is important to them and how to communicate that to the health profes-sionals guiding their care.”—Doody’s Reviews

An American Journal of nursing “best consumer heath book 2011”


neW

Provides the Practitioner with an Innovative Program to Guide from Cancer and its Treatment





87

High Yield and Extremely Easy to Read Review

Tumor board reviewsGuidelines and Case Reviews in OncologyEdited by Robert F. Todd, III, MD, PhD, Chair of Medicine, Baylor College of Medicine, Kathleen A. Cooney, MD, Chief of Hematology/Oncology, Michigan University School of Medicine, Teresa Hayes, MD, Assistant Professor of Oncology, Baylor College of Medicine, Martha Pritchett Mims, MD, Chief of Hematology/Oncology, Baylor College of Medicine, and Francis P. Worden, MD, Clinical Associate Professor of Oncology and Fellowship Director, Michigan Univer-sity School of Medicine

Tumor Board Reviews provides comprehensive coverage of all topics in oncology. Each topic is introduced with a short overview, followed by a sequence of specific presentations organized by disease classification. Each disease classification includes a concise summary of current practice standards followed by a “tumor board” case presentation. These case presentations demonstrate clinical applica-tions and are accompanied by expert comment and teaching points drawn from the case.

The combination of guideline summaries with cases illustrating clinical applica-tions is unique. Guidelines (mostly issued through NCCN) are issued and updated continually but often there is no real explanation of how they should be applied. The combination of guidelines summaries with case discussions make this volume a unique tool for keeping current with clinical guidelines and provides the reader with a clear understanding of applications of new information for use in daily practice.

FEATURES OF TUMOR BOARD REVIEWS INCLUDE:

r Comprehensive coverage of all areas of oncology

r Presentation of most recent guidelines and management standards in concise, user-friendly format

r In depth “tumor board” presentations showing clear clinical applications

r Special focus on indications and use of new drugs, and treatment of new side effects

r Expert analysis and commentary

conTenTS: 1. Head and Neck Cancer, 2. Thyroid Cancer, 3. Non-Small Cell Lung Cancer, 4. Small Cell Lung Cancer, 5. Breast Cancer, 6. Esophageal Cancer, 7. Gastric Cancer, 8. Pancreatic Cancer, 9. Neuroendocrine Cancer, 10. Hepatobiliary Cancers, 11. Colorectal Cancer, 12. Anal Cancer, 13. Prostate Cancer, 14. Testicu-lar Cancer, 15. Kidney Cancer, 16. Bladder Cancer, 17. Cervical Cancer, 18. Uterine Cancer, 19. Ovarian Cancer, 20. Melanoma, 21. Bone Sarcoma. 22. Soft Tissue Sarcoma, 23. Primary Brain Tumors, 24. Cancer of Unknown Primary, 25. Hodgkins Disease, 26. Non-Hodgkins Lymphoma, 27. Multiple Myeloma, 28. Acute Leukemia, 29. Chronic Myeloid Leukemia, 30. Chronic Lymphocytic Leukemia, 31. Myelodysplastic Syndrome

December 2011 • 400 pp • Hardcover • 978-1-936287-17-8 E-book ISBN • 978-1-617050-46-6 • $95.00 / $80.75

A Timely and Thorough Review of the Neurologic Complications of Anti-Cancer Treatments

neurologic complications of cancer TherapyEditors: Patrick Y. Wen, MD, Director, Division of Neuro-Oncology, Brigham & Women’s Hospital, David Schiff, MD, Co-Director, Neuro-Oncology Center, University of Virginia, and Eudocia C. Quant, MD, Neurology Fellow, Brigham & Women’s Hospital

Neurologic side effects of cancer therapy can inhibit treatment, can be dose-limiting and can diminish quality-of-life. Neurotoxicity related to cancer therapy is a common problem in oncology practice and in clinical neurology. Recognition of neurologic complications of anticancer therapy is necessary due to potential confusion with metastatic disease, paraneoplastic syndromes or comorbid neurologic disorders that do not require reduction or discontinuation of therapy.

Neurologic Complications of Cancer Therapy provides comprehensive coverage of the recognition and management of neurologic symptoms related to cancer therapy. The book includes sections on systemic therapy discussed by both agent and adverse event. The section on adverse events is particularly valuable to clinicians, allowing them to consult by symptom in cases where multiple agents have been administered and the source of the complication is uncertain. The systemic therapy section includes coverage of immunologic agents, biologics, and targeted therapies. The book also features sections on the complications of radiation therapy, complications of surgery and high-dose chemotherapy, and stem cell transplantation.

NEUROLOGIC COMpLICATIONS OF CANCER THERApY FEATURES:

r A widely recognized team of editors

r Systemic therapy covered by therapeutic agent and by adverse event, enabling a “problem-oriented” approach for the clinician

r Coverage of newer modalities including immunologic agents, biologics, and targeted therapies

r Complete sections on complications of radiation therapy, surgery, high-dose chemotherapy, and stem-call transplantion

conTenTS: PART 1: NEUROLOGIC COMPLICATIONS OF SYSTEMIC THERAPIES: ACCORDING TO AGENT: 1. Alkylating agents; 2. Antimetabolites 3. Plant Alkaloids; 4. Topoisomerase inhibitors; 5. Epothilones; 6. Amino acid degraders; 7. Corticosteroids; 8. Immunomodulatory agents; 9. Immu-nosuppressants; 10. Biologic Agents; 11. Targeted Therapies; 12. Hormonal therapies; 13. Supportive therapies; According to adverse event: 14. Cognitive function; 15. Central nervous system complications (except cognitive dysfunction); 16. Peripheral nervous system complications (excluding muscle and NMJ disorders); 17. Neuromuscular junction and myopathy; PART 2: NEUROLOGIC COMPLICATIONS OF RADIATION THERAPY: 18. Mechanisms of radiation damage; 19. Early CNS complications; 20. Late-delayed CNS complications; 21. Radiation-induced tumors; 22. Radiation vasculopathy; 23. Spinal cord damage; 24. Peripheral nerve damage; PART 3: NEUROLOGIC COMPLICATIONS OF SURGERY: 25. Surgery; PART 4: NEUROLOGIC COMPLICATIONS OF HEMATOPOIETIC STEM CELL TRANS-PLANTATION: 26. Hematopoietic stem cell transplantation

2011 • 350 pp • Hardcover • 978-1-932687-07-9 • E-book ISBN • 978-1-617050-19-0 • $99.00 / $84.15

“...extremely helpful in refreshing my memory on a broad range of treatments. This is a very high yield and extremely easy to read review. The discussions include recent clinical trial data and well-designed treatment paradigms”—Doody’s Reviews





109

lung cancerGuest Editor: Athanassios Argiris, MD, FACP, A.B. Alexander Distinguished Chair in Oncology; Professor and Chief, Division of Hematology/Oncology; Associate Director for Cancer Research; Cancer Therapy and Research Center, UT Health Science Center at San Antonio, San Antonio, Texas

With contributions from internationally recognized experts, Lung Cancer details the current management of lung cancer and reviews new therapies in development for lung cancer, with an emphasis on therapeutic exploitation of the heterogeneous nature of lung tumors at the molecular level. Coverage includes discussion of multiple new agents that have been shown to impact overall survival as well as articles covering molecular biology of lung cancer, chemotherapy regimens for lung cancer, the emergence of maintenance therapy, the complexity of radiothera-py in the chest, the impact of adjuvant chemotherapy for resected non-small cell lung cancer, surgical considerations for early-stage lung cancer, and more. This book is a valuable tool for clinicians, nurses, researchers, medical students, residents, and fellows.conTenTS: 1. Molecular Biology of Lung Cancer and Therapeutic Implications, 2. Chemotherapy Options for Advanced Non-Small Cell Lung Cancer, 3. Pros and Cons of Maintenance Therapy for Advanced Non-Small Cell Lung Cancer, 4. Antiangiogenic Agents in Lung Cancer, 5. Emerging Novel Targeted Agents for Lung Cancer, 6. State-of-the-Art Treatment of Lung Cancer in the Elderly, 7. Surgical Approaches to Early Stage Lung Cancer, 8. Advances in First- and Second-Line Therapy of Small Cell Lung Cancer, 9. Adjuvant Chemotherapy for Early Stage Non-Small Cell Lung Cancer, 10. Advancements in Radiotherapy for Lung Cancer, 11. Emerging Concepts in the Treatment of Epidermal Growth Factor Receptor Mutation-Positive Lung CancerMay 2012 • 200 pp. • Hardcover • 978-1-936287-52-9 • E-book ISBN 978-1-617050-97-8 • $85.00 / $72.25

Prostate cancerGuest Editor: James L. Gulley, MD, PhD, FACP, Director, Clinical Immunotherapy Group, Senior Investigator, National Cancer Institute

With contributions from experts across the United States and Canada, prostate Cancer details the current management of prostate cancer and reviews new therapies in development for prostate cancer, with an emphasis on castration-resistant prostate cancer (CRPC). Coverage includes discussion of multiple new

agents that have been shown to impact overall survival or improve skeletal-related events in metastatic CRPC as well as articles covering new data on screening and prevention, integration of surgery and radiation with newly emerging medical therapies, and coverage of the newest developments in immunotherapy. This book is a valuable tool for clinicians, nurses, researchers, medical students, residents, and fellows.conTenTS: 1. Updates in Prostate Cancer Prevention, 2. Prostate Cancer Screening, 2011, 3. Current Surgical Ap-proaches to Primary Prostate Cancer Treatment, 4. Updates in Radiation Therapy for Prostate Cancer: Dose Matters, 5. An Update on Androgen-Deprivation Therapy for Advanced Prostate Cancer, 6. Novel Androgen Receptor Therapeutic Targets for Advanced Prostate Cancer, 7. New Understanding of Metabolic Complications of Androgen-Deprivation Therapy, 8. Current State of Docetaxel-Based Therapy in Castration-Resistant Prostate Cancer, 9. Second-Line Chemo-therapy for Castration-Resistant Prostate Cancer, 10. Emerging Role of Immunotherapy in the Treatment of Prostate Cancer, 11. Novel Bone-Targeted Therapy in Metastatic Prostate Cancer, 12. Emerging Treatment Strategies for Meta-static Prostate Cancer: The Next Step ForwardDecember 2011 • 200 pp. • Hardcover • 978-1-936287-46-8 • E-book ISBN 978-1-935281-91-7 • $85.00 / $72.25

A new cutting-edge review Publication in cancer Therapeutics

emerging cancer Therapeutics VOLUME 2, 2011

EDITOR-IN-CHIEF: Jame Abraham, MD, FACP, Bonnie Wells Wilson Distinguished Professor and Eminent Scholar, Chief, Section of Hematology-Oncology, and Medical Director, Mary Babb Randolph Cancer Center, West Virginia University

Published three times a year Emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both solid and hematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for manage-ment such as molecular imaging. Emerging Cancer Therapeutics is a valuable tool for clini-cians, nurses, researchers, medical students, residents, and fellows.

FEATURES OF EMERGING CANCER THERApEUTICS INCLUDE:

r Editorial board of nationally recognized experts across the spectrum of Cancer Therapeutics

r In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Cancer Therapeutics

r Issues edited by an authority in specific subject area

r Focuses on major topics in Cancer Therapeutics with in-depth articles covering advances in clinical and translational research developments, as well as clinical applications and experience

MelanomaGuest Editor: William H. Sharfman, MD, Associate Professor of Oncology, Associate Professor of Dermatology, Johns Hopkins School of Medicine

Melanoma provides a comprehensive review for practitioners on the current status of melanoma treatment. Due to recent drug approvals and increasing ability to offer combined agents, there are many more treatment options available to melanoma patients than even a few years ago. Especially significant are the recent FDA approval of the immunotherapeutic agent ipilimumab for metastatic melanoma, and new agents targeting the BRAF gene in malignant melanoma. There is also coverage of the most recent data pertaining to surgical management, staging and prevention, and melanoma in children.conTenTS: 1. Preventing Melanoma; 2. The Evolution of the Staging System; 3. Pathology; 4. Melanoma in Children; 5. Controversies in the Surgical Management of Melanoma; 6. Adjuvant Therapy of High Risk Melanoma; 7. Update on the Role of IL-2 and Chemotherapy for Metastatic Melanoma; 8. Targeting BRAF in Malignant Melanoma; 9. Targeted Therapy in Ocular and Mucosal Melanoma; 10. Ipilimumab in the Treatment of Malignant Melanoma; 11. Immunotherapies in Development for Treatment of Melanoma; 12. TIL Therapy; 13. Updated Approach to the Patient with Metastatic Melanoma; 14. The Next Decade- Promising Basic and Translational ResearchDecember 2012 • 224 pp. • Hardcover • 978-1-936287-79-6 • E-book ISBN 978-1-617051-61-6 • $85.00 / $72.25

lymphomaGuest Editor: John Sweetenham, MD, Professor of Medicine, Medical Director, UCSD Nevada Cancer Institute, Las Vegas,

This volume in Emerging Cancer Therapeutics provides a comprehensive review for practitioners on the current status of lymphoma subtypes. All of the chapters in Lymphoma are written by international experts in the field, address current management across the spectrum of lymphoma subtypes and are multidisciplinary in scope. Uniquely Lymphoma provides a disease subtype-specific review of new and emerging therapies for lymphoid malignancy.conTenTS: 1. Head and Neck Cancers, 2. Central Nervous System, 3. Breast Cancers, 4. Lung Cancer, 5. Gastrointestinal Cancers, 6. Genitourinary Cancers, 7. Gynecologic Cancers, 8. Lymphomas, 9. Pediatric CancersSeptember 2012 • 200 pp. • Hardcover • 978-1-936287-78-9 E-book ISBN 978-1-617051-31-9 • $85.00/$72.25

Melanoma

William H. SharfmanGuest Editor

Emerging Cancer TherapeuticsEditor-in-Chief: Jame Abraham ECAT

James L. Gulley, MD, PhD, FACP, Guest Editor

Emerging Cancer Therapeutics is a trinary, hard cover, periodical that is designed to provide an up-to-date evidence-based review of a dedicated emerging cancer therapy topic of interest to clinicians and scientists who are involved in the care of patients receiving cancer treatment. It will serve as both a reference and instructional tool for students, housestaff, fellows, practicing clinical oncologists, radiation oncologists, surgical oncologists, cancer biologists, and interdisciplinary colleagues throughout the oncology spectrum.

With contributions from experts across the United States and Canada, Prostate Cancer details the current management of prostate cancer and reviews new therapies in development for prostate cancer, with an emphasis on castration-resistant prostate cancer (CRPC). Coverage includes discussion of multiple new agents that have been shown to impact overall survival or improve skeletal-related events in metastatic CRPC as well as articles covering new data on screening and prevention, integration of surgery and radiation with newly emerging medical therapies, and coverage of the newest developments in immunotherapy. This book is a valuable tool for clinicians, nurses, researchers, medical students, residents, and fellows.


Prostate CancerVolume 2, Issue 3, 2011

11 W. 42nd StreetNew York, NY 10036www.demosmedpub.com

Included in Prostate Cancer� Updates in Prostate Cancer Prevention� Prostate Cancer Screening, 2011� Current Surgical Approaches to Primary Prostate Cancer Treatment� Updates in Radiation Therapy for Prostate Cancer: Dose Matters� An Update on Androgen-Deprivation Therapy for Advanced Prostate Cancer� Novel Androgen Receptor Therapeutic Targets for Advanced Prostate Cancer� New Understanding of Metabolic Complications of Androgen-Deprivation Therapy� Current State of Docetaxel-Based Therapy in Castration-Resistant Prostate Cancer� Second-Line Chemotherapy for Castration-Resistant Prostate Cancer� Emerging Role of Immunotherapy in the Treatment of Prostate Cancer � Novel Bone-Targeted Therapy in Metastatic Prostate Cancer� Emerging Treatment Strategies for Metastatic Prostate Cancer: The Next Step Forward

9 781936 287468

Recommended Shelving Category: Oncology

Emerging Cancer Therapeutics

20123:2

Lymp

hom

aECAT

Lymphoma

John Sweetenham Guest Editor


James L. Gulley, MD, PhD, FACP, Guest Editor

Emerging Cancer Therapeutics is a trinary, hard cover, periodical that is designed to provide an up-to-date evidence-based review of a dedicated emerging cancer therapy topic of interest to clinicians and scientists who are involved in the care of patients receiving cancer treatment. It will serve as both a reference and instructional tool for students, housestaff, fellows, practicing clinical oncologists, radiation oncologists, surgical oncologists, cancer biologists, and interdisciplinary colleagues throughout the oncology spectrum.

With contributions from experts across the United States and Canada, Prostate Cancer details the current management of prostate cancer and reviews new therapies in development for prostate cancer, with an emphasis on castration-resistant prostate cancer (CRPC). Coverage includes discussion of multiple new agents that have been shown to impact overall survival or improve skeletal-related events in metastatic CRPC as well as articles covering new data on screening and prevention, integration of surgery and radiation with newly emerging medical therapies, and coverage of the newest developments in immunotherapy. This book is a valuable tool for clinicians, nurses, researchers, medical students, residents, and fellows.


Prostate CancerVolume 2, Issue 3, 2011

11 W. 42nd Street New York, NY 10036www.demosmedpub.com

Included in Prostate Cancern Updates in Prostate Cancer Preventionn Prostate Cancer Screening, 2011n Current Surgical Approaches to Primary Prostate Cancer Treatmentn Updates in Radiation Therapy for Prostate Cancer: Dose Mattersn An Update on Androgen-Deprivation Therapy for Advanced Prostate Cancern Novel Androgen Receptor Therapeutic Targets for Advanced Prostate Cancern New Understanding of Metabolic Complications of Androgen-Deprivation Therapyn Current State of Docetaxel-Based Therapy in Castration-Resistant Prostate Cancern Second-Line Chemotherapy for Castration-Resistant Prostate Cancern Emerging Role of Immunotherapy in the Treatment of Prostate Cancer n Novel Bone-Targeted Therapy in Metastatic Prostate Cancern Emerging Treatment Strategies for Metastatic Prostate Cancer: The Next Step Forward

9 781936 287468

Recommended Shelving Category: Oncology

Emerging Cancer Therapeutics

20123:2

Lymp

hom

aECAT

A DooDY’S core TITle 2012 ****4 Stars! “…A great resource for balanced perspectives on current concepts and treatments for all stages of the disease.” —Doody’s Reviews

ForThcoMIng DeceMber 2012





1211

leukemiaGuest Editor: Uday R. Popat, MD, Associate Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, University of Texas M. D. Anderson Cancer Center, Houston, TX

conTenTS: 1. Hematopathology and Diagnostic Studies, 2. Acute Myeloid Leukemia, 3. Chronic myeloid Leukemia, 4. Acute Lymphoblastic Leukemia in Adults, 5. Acute Promyelo-cytic Leukemia, 6. Myelodysplastic Syndrome, 7. Myeloproliferative Disorders, 8. Chronic

Lymphocytic Leukemia, 9. Reduced intensity Allogeneic Transplantation in Leukemia,10. Alternative Donor Stem Cell Transplantation in Patients with Leukemia, 11. Immunotherapy in Leukemia, 12. Novel and Targeted Therapy in Leukemia, 13. Infections in Patients with Leukemia

2011 • 200 pp • Hardcover • 978-1-933864-68-6 • E-book ISBN 978-1-935281-42-9 • $85.00 / $72.25

renal cancerGuest Editor: Walter M. Stadler, MD, Fred C. Buffet Professor of Medicine and Surgery, Associate Dean for Clinical Research, Director, Genitourinary Program, The University of Chicago Medical Center

Renal cancer treatment has undergone major changes over the course of the past few years and Renal Cancer addresses current best practices in the light of the most recent evidence. All of the chapters are written by international experts in the field, address the common clinical scenarios in renal cancer and are multidisciplinary in scope covering surgical, medical, and radiation therapy. Chapters examining emerging and novel therapeutic targets, and the management of both CNS, and skeletal metastases in renal cancer round out the coverage.conTenTS: 1. The Biology of Renal Cancer, 2. Renal Cell Carcinoma: Current Concepts of Morphologic Subclassification and Clinical Relevance, 3. Imaging Renal Carcinoma, 4. Management of Small Renal Masses 5. Surgical Management of Renal Cancer, 6. Nonsystemic Approaches to the Management of Metastatic Renal Cell Carcinoma, 7. IL-2 and Other Immunotherapy in Renal Cancer, 8. VEGF Pathway-Directed Therapies in Renal Carcinoma, 9. mTOR Pathway-Directed Agents in Renal Cell Carcinoma, 10. Emerging and Novel Therapeutic Targets in Renal Cancer, 11. Management of Central Nervous System Metastases from Renal Cancer, 12. Evaluation and Management of Skeletal Metastases


breast cancerGuest Editor: Antoinette R. Tan, MD, MHSc, Assistant Professor of Medicine, The Cancer Institute of New Jersey

Breast Cancer offers a comprehensive and in-depth review of the current literature of breast cancer. Chapters examine risk factors and

prevention strategies, trends and developments in imaging, surgical management, radiotherapy advances, adjuvant endocrine and chemotherapies, targeted metastatic therapy, and the role of bisphosphonates and novel bone agents in breast cancer.


Multiple MyelomaGuest Editor: Shaji Kumar, MD, Associate Professor of Medicine, Division of Hematology, Mayo Clinic, Rochester

Management options and outcomes for individuals with multiple myelomas, have improved dramatically with the introduction of che-motherapy. Even further improvements in prognosis have occurred because of the introduction of newer therapies such as pulse cortico-steroids, thalidomide, bortezomib, and autologous and allogeneic stem cell transplantation.

The clinician is better placed to offer effective therapy but at the same time is challenged to keep abreast of the rapidly changing treatment landscape and the newly emerging data. Multiple Myeloma provides a comprehensive and in-depth review of this group of malignancies.


gastrointestinal MalignanciesGuest Editor: M. Wasif Saif, MD, MBBS, Associate Professor of Medicine, Medical Oncology, Director, GI Cancers Program, Yale Cancer Center, Yale University School of Medicine Professor of Medicine

Gastrointestinal Malignancies provides a comprehensive and in-depth review of this group of malignancies. This volume reviews the current literature, provides critical evaluations of the data, and offers evidence-based recommendations. The chapters update the current screening tools for colon cancers, assessment of predictive markers such as k-Ras and BRAF in the management of colon cancer as well as the state-of-the-art for use of both cytotoxic chemotherapy and the incorporation of newer biological therapies.

2010 · 196 pp · Hardcover · 978-1-933864-90-7 · E-book ISBN · 978-1-935281-43-6 · $89.00 / $75.65

“This is a great resource for students, fellows, and clinicians with an interest in leukemia. It offers an important alternative to the less con-cise textbooks and less in-depth journal review articles on leukemia. —Doody’s Reviews

“ The book highlights all current aspects of breast cancer man-agement (imaging, surgery, radiotherapy, and chemotherapy). The book is particularly good at summarizing the relevant and important clinical studies. overall, this book does an excellent job of presenting current research studies in an easy to read format.” —Doody’s Reviews

“...Provide up-to-date, detailed information on myeloma. ...Important points are covered...Suitable for busy practitioners who want a quick overview of selected topics.”—Doody’s Reviews

“A clinically useful and concise review of a range of current and emerging therapies for gastrointestinal malignancies is presented in this book.” —Doody’s Reviews

A new cutting-edge review Publication in cancer Therapeutics





1413

lung cancera Multidisciplinary approach to Diagnosis and ManagementKemp H. Kernstine, MD, PhD, Professor of Surgery, Chairman, Division of Thoracic Surgery, Robert Tucker Hayes Distinguished Chair in Cardiothoracic Surgery, University of Texas, Southwestern School of Medicine and Karen L. Reckamp, MD MS, Assistant Professor of Medicine, Department of Medical Oncology & Experimental Therapeu-tics and Hematology & Hematopoietic Cell Transplant, City of Hope Comprehensive Cancer Center and Beckman Research Institute

Over the course of the last decade, the treatment of lung cancer has evolved quite rapidly. New sci-entific and clinical advances have modified the standard care and led to improved patient outcomes. At the same time, the treatment of lung cancer has become increasingly complex, requiring the comprehensive review and assessment of multiple issues, genetics, radiology, surgery, reconstruc-tion, chemotherapy, and more. As a result the harmony and open communication between these specialties facilitated by a multidisciplinary team approach are crucial in providing the best care to patients and ensuring successful treatment.

Lung Cancer, written by a multidisciplinary team of authors representing a range of disciplines, is a valuable resource for physicians, fellows, nurses physician assistants, physical therapists, and all health care providers involved in the treatment of lung cancer. Lung Cancer summarizes the state-of-the-art issues related to the treatment of lung cancer and describes an approach for optimal multidisciplinary care for individuals who are at higher risk of or who have been diagnosed with lung cancer.

approach in breast reconstruction, 10.Multidisciplinary approach in the treatment of metastatic disease, 11.Multidisci-plinary approach in the management of locally recurrent disease, 12.Multidisciplinary approach to the patient’s quality of life, 13.Psychiatric Issues in Breast Cancer, 14.Multidisciplinary considerations: Racial disparities in breast cancer, 15.Multidisciplinary Breast Cancer Care in the Community, 16.Future directions in the treatment of breast cancer

Kemp H. Kernstine, MD PhD, Professor of Surgery, Chairman,Division of Thoracic Surgery, Robert Tucker Hayes Distinguished Chair in Cardiothoracic Surgery, University of Texas, Southwestern School of Medicine and Karen L. Reckamp, MD MS, Assistant Professor of Medicine, Department of Medical Oncology & Exper-imental Therapeutics and Hematology & Hematopoietic Cell Trans-plant, City of Hope Comprehensive Cancer Center and Beckman Research Institute

Over the course of the last decade, the treatment of lung cancer has evolved quite rapidly. New scientific and clinical advances have modified the stan-dard of care and led to improved patient outcomes. At the same time, the treatment of lung cancer has become increasingly complex, requiring the comprehensive review and assessment of multiple issues, genetics, radiology, surgery, reconstruction, chemotherapy, and more. As a result the harmony and open communication between these specialties facilitated by a multidisciplinary team approach are crucial in providing the best care to patients and ensuring successful treatment.

Lung Cancer, written by a multidisciplinary team of authors representing a range of disciplines, is a valuable resource for physicians, fellows, nurses, physician assistants, physical therapists, and all health care providers involved in the treatment of lung can-cer. Lung Cancer summarizes the state-of-the-art issues related to the treatment of lung cancer and describes an approach for optimal multidisciplinary care for individuals who are at higher risk of or who have been diagnosed with lung cancer.

1. Overview, 2. Multidisciplinary Primary Care Approach to the Management of Lung Cancer: Non-small Cell Lung Cancer, 3. Pathology of Lung Cancer, 4. The New Lung Cancer Staging System, 5. Lung Cancer Screening and Prevention of Cancer, 6. Imaging in Lung Cancer, Treatment According to Stage: 7. Early Stage Local Disease NSCLC, Surgical Therapy Options, 8. Is There a Role for Surgical Treatment in Patients with Local Small Cell Lung Cancer?, 9. Evaluation, Management and Medical Therapy of Small Cell lung Cancer, 10. Stages IB to IIIA NSCLC: The Case for Induction vs. Adjuvant Chemotherapy, 11. Stage IIIA Disease: The Case Against Surgical Involvement, 12. Stage IIIA: The Case for Surgical Involvement, 13. Stage IIIB and IV: Potential Surgical Opportunities to Improve Survival and the Data Supporting This, 14. Stage IIIB and IV Disease NSCLC: Primary Therapy, 15. Stage IIIB and IV Disease NSCLC: Recurrent Disease, 16. Conformal Radiation Therapy for NSCLC and Small Cell Lung Cancer: Primary and Metastatic and Recurrent Disease, 17. Stereotactic Radiation Therapy for Primary and Metastatic and Recurrent Disease, Special Circumstances: 18. Tracheobronchial Cancers: Brachytherapy, Laser Resection, Endobronchial Resection, PDT, 19. Targeting Pathways in NSCLC and SCLS, 20. Role of Personalized Medicine: Now and the Future, 21. Lung Cancer in the Elderly, 22. Lung Cancer in Minorities, 23. Immunological Approaches to the Treatment of Lung Cancer, 24. Multidisciplinary Approach to Palliative Management and Symptom Management of Disease, 25. Multidisciplinary approaches to the Psycho-oncologic Management of Disease, 26. Multidisciplinary Management in the Community Setting, 27. Future Directions in the Multidisciplinary Management of Lung Cancer

1.Importance of the multidisciplinary approach to breast cancer, 2.Multidisciplinary approach to the preven-tion & screening of breast CA, 3.Intake of new patients for Multidisciplinary Clinics, 4.Multidisciplinary issues for newly diagnosed patients, 5.””Medical and Surgical Management of Atypical Hyperplasia and Lobular Carcinoma in situ, 6.Multidisciplinary approach in the treatment of Ductal Carcinoma in situ, 7.Multidisciplinary approach in the treatment of early breast cancer, 8.Multidisciplinary approach in the treatment of locally advanced breast cancer, 9.Multidisciplinary







current Multidisciplinary oncology

2010 • 272 pp • Hardcover • 978-1-936287-06-2 E-book ISBN • 978-1-617050-18-3 • $130.00 / $110.50


breast cancera Multidisciplinary approach to Diagnosis and ManagementAlphonse G. Taghian, MD, PhD, Associate Professor of Radiation Oncology, Harvard Medical School, Chief of Breast Service, Massa-chusetts General Hospital, Barbara L. Smith, MD, PhD, Associate Professor of Surgery, Harvard Medical School, Director, Breast Program, Massachusetts General Hospital, and John K. Erban, MD, Associate Professor of Medicine, Harvard Medical School, Director, Clinical Programs and Co-Director, Gillette Center for Breast Cancer, Massachu-setts General Hospital

Over the course of the last decade, the treatment of breast cancer has evolved quite rapidly. New scientific and clinical advances have modified the standard of care and led to improved patient outcomes. At the same time, the treatment of breast cancer has become increasingly complex, requiring the comprehensive review and assessment of multiple issues, genetics, radiology, surgery, reconstruction, fertility radiation, chemotherapy, and more. As a result the harmony and open communication between these specialties facilitated by a multidisciplinary team approach are crucial in providing the best care to patients and ensuring successful treatment.

Breast Cancer, by a multidisciplinary team of authors representing a range of disciplines, is a review for physicians, fellows, nurses physician assistants, physical therapists, and all health care providers involved in the treatment of breast cancer. Breast Cancer summarizes the state-of-the-art issues related to the treatment of breast cancer and describes an approach for optimal multidis-ciplinary care for women who are at higher risk of or who have been diagnosed with breast cancer.

current Multidisciplinary oncologySERIES EDITOR: Charles R. Thomas, Jr., MD, Professor and Chairman, Department of Radiation Medicine, and Professor of Hematology/ Oncology, Knight Cancer Institute, Oregon Health Sciences University

The Current Multidisciplinary Oncology series consolidates and integrates the varied aspects of multidisciplinary care for major topics in oncology, including breast, lung, prostate, head and neck and more.

The volumes in the Current Multidisciplinary Oncology series represent all related topic areas, including oncology, radiation oncology, pain, pathology, imaging, psychological support and the primary disease. In addition, each volume include a chapter focusing on special populations and the disease’s impact / difference on them, discussion of Future Directions and Quality of Life issues, and each volume a chapter written by a private practice oncologist

A New Resource That Will Aid in the Multidisciplinary Approach to Solid Tumors

“This is a high quality book, quite relevant and useful, especially in this fast changing area in which multidisciplinary care is state-of-the-art approach.” —Doody’s Reviews

“ ...This textbook is very informative and is current with the contemporary status of breast cancer care. It presents both referenced tables and online resources to make this a very good resource for caregivers.” —International Journal of Radiation, biology, Physics, Volume 78, No. 2

“ ...very informative and well-structured monograph on breast cancer care. In summary, this textbook is very informative and is current with the contemporary status of breast cancer care. It presents both referenced tables and online resources to make this a very good resource for caregivers.” —The ASC Bulletin, Volume XLVII, Number 6, November 2010

“overall, the editors have assembled a useful reference that reviews the concepts essential to lung cancer management. As oncology continues to evolve into a number of disease subspecialties, resources like this will be increasingly valuable to all healthcare professionals involved in the care of cancer patients.”—Doody’s Reviews

Alphonse G. Taghian, MD,PhD, Associate Professor of Radiation Oncology, Harvard Medical School, Chief of Breast Service, Mas-sachusetts General Hospital, Barbara L. Smith, MD, PhD, Associ-ate Professor of Surgery, Harvard Medical School, Director, Breast Program, Massachusetts General Hospital, and John K. Erban, MD, Associate Professor of Medicine, Harvard Medical School, Director, Clinical Programs and Co-Director, Gillette Center for Breast Cancer, Massachusetts General Hospital

Over the course of the last decade, the treatment of breast cancer has evolved quite rap-idly. New scientific and clinical advances have modified the standard of care and led to improved patient outcomes. At the same time, the treatment of breast cancer has become increasingly complex, requiring the comprehensive review and assessment of multiple issues, genetics, radiology, surgery, reconstruction, fertility radiation, chemotherapy, and more. As a result the harmony and open communication between these specialties facilitated by a multidisciplinary team approach are crucial in providing the best care to patients and ensuring successful treatment.

Breast Cancer, by a multidisciplinary team of authors representing a range of disci-plines, is a review for physicians, fellows, nurses, physician assistants, physical thera-pists, and all health care providers involved in the treatment of breast cancer. Breast Cancer summarizes the state-of-the-art issues related to the treatment of breast cancer and describes an approach for optimal multidisciplinary care for women who are at higher risk of or who have been diagnosed with breast cancer.











1615

Gregory M.M. Videtic, MD, CM, FRCPC, Residency Program Di-rector, and Associate Professor of Medicine, Department of Radiation Oncology, and Andrew D. Vassil, MD, Resident Physician, Depart-ment of Radiation Oncology, both of the Cleveland Clinic Foundation

The Handbook of Radiation Treatment Delivery is a focused pocket-sized handbook designed for Radiation Oncology trainees and residents, to serve as an up-to-date, quick resource to lead them through all of the standard steps to plan and deliver radiotherapy for

all major malignancies. The goal of the Handbook is to provide evidence-based information but also to be reflective of the knowledge gained through experience in practice. All chap-ters represent a joint collaboration between residents and staff radiation oncologists, in the Department of Radiation Oncology at the Cleveland Clinic.

Throughout the Handbook, the focus is on a series of steps to follow in order to successful-ly complete effective radiotherapy planning. Sections are organized by body site or system, whichever proved best for consistency in presenting the general principles of planning. Also included are specialized topics such as palliative therapy and pediatrics. After a discussion of general planning requirements, each specific subsite within a given section then provides more specific details on approaches to radiotherapy planning.

1. General Physics Principles, 2. Tools for Simulation and Treatment, 3. Central Nervous System Radiothera-py, 4. Head and Neck Radiotherapy, 5. Breast Radiotherapy, 6. Thoracic Radiotherapy, 7. Gastrointestinal (Nonesophageal) Radiotherapy, 8. Genitourinary Radiotherapy, 9. Gynecologic Radiotherapy, 10. Lymphoma and Myeloma Radiotherapy, 11. Soft Tissue Sarcoma Radiotherapy, 12. Pediatric Radiotherapy, 13. Palliative Radiotherapy

Robert I. Haddad, MD, Clinical Director, Head and Neck Oncology, Dana Farber Cancer Institute, Harvard Medical School.

The treatment of head and neck cancer is extremely challenging and in-volves insight and expertise from multiple disciplines. Multidisciplinary Management of Head and Neck Cancer is a comprehensive textbook looking at different aspects of head and neck cancer, including the diag-nosis, treatment, and outcomes for patients with this disease. The chapters written by world-renowned experts cover the entire discipline of head and

neck oncology and include discussion of the role of HPV infections, advances in radiotherapy, new surgical techniques, novel agents in thyroid therapy and more. The book is designed to be both practical and comprehensive for the physicians treating this complex disease.

FEATURES OF MULTIDISCIPLINARY MANAGEMENT OF HEAD AND NECK CANCER INCLUDE:

A chapter on the role of HPV infections in head and neck cancer

A chapter on new advances in radiotherapy for head and neck cancer, including review of IMRT, new standards and potential pitfalls

Detailed discussion of the role of chemotherapy in head and neck cancer, including commonly used drugs and how to combine them with radiotherapy to improve patient outcomes

Detailed discussion on incorporating novel agents with radiotherapy

Detailed discussion of novel therapeutics in head and neck cancer, including new drugs and biologics 1. Role of HPV infections in head and neck cancer, 2.New advances in radiotherapy for head and neck cancer, 3.

Molecularly Targeted Agents in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck, 4. Induction chemo-therapy in locally advanced head and neck cancer: an evolving concept, 5. New surgical techniques in head and neck cancer, 6. Incorporating novel agents with chemotherapy and radiotherapy for the treatment of locally advanced squamous cel carcinoma of the head and neck, 7. Concurrent chemoradiotherapy in head and neck cancer, 8. Novel agents in thyroid cancer, 9. Prevention and treatment of dysphagia and aspiration in head and neck cancer, 10. Functional imaging of the head and neck with positron emission tomography (PET), 11. Diagnostic and therapeutic advances in multidisciplinary care for nasopharyngeal cancer

New and Forthcoming Titles in Oncology

2010 • 232 pp • Hardcover • 978-1-933864-55-6 • E-book ISBN • 978-1-617050-12-1 • $89.00/$75.65

Multidisciplinary Management of head and neck center

2010 • 1,024 pp • 48 page Color Insert Hardcover • 978-1-933864-78-5 E-book ISBN 978-1-617050-14-5 • $250.00 / $212.50

EDITOR-IN-CHIEF: Minesh P. Mehta, MD, FASTRO, Professor, Department of Human Oncology, University of Wisconsin

EDITORS: Susan M. Chang, MD, Professor, Vice Chair of Neurological Surgery, Director, Division of Neuro-On-cology, University of California San Francisco, Abhijit Guha, MSc, MD, FRCSC, FACS, Professor of Surgery (Neurosurgery), Toronto Western Hospital, Hudson Chair in Neuro-Oncology, University of Toronto, Herbert B. Newton, MD, FAAN, Professor of Neurology, Neurosurgery, and Oncology, Esther Dardinger Endowed Chair in Neuro-

Oncology, Department of Neurosurgery, Dardinger, Neuro-Oncology Center, Ohio State Univer- sity Medical Center and Michael A. Vogelbaum, MD, PhD, FACS, The Robert and Kathryn Lamborn Chair for Neuro-Oncology, Department of Neurological Surgery, Cleveland Clinic

Neuro-oncologic (brain and spine) cancers account for 19,000 new cases and 13,000 deaths per year. The early and proper diagnosis of these virulent cancers is critical to patient out-comes and diagnosis and treatment strategies are continually evolving.

The multidisciplinary team that manages these patients involves medical and radiation oncology, neurosurgery, neuroimaging, nurses and therapists.

Principles and Practices of Neuro-Oncology establishes a new gold standard in care through a comprehensive and multidisciplinary text covering all aspects of neuro-oncology. Six major sections cover all topics related to epidemiology and etiology, clinical features and supportive care, imaging, neuroanatomy and neurosurgery, medical oncology and targeted therapies, and radiation oncology for adult and pediatric cancers. Expert contributors from multiple disciplines provide detailed and in-depth discussions of the entire fi eld of neuro-oncology including histopathologic harmonization, quality of life and therapeutic changes in terms of combined modality treatments, advanced radiation techniques, the advent of new drugs, especially targeted agents, and the tantalizing early promise of personalized thera-peutic approaches.

With contributions from over 180 authors, numerous diagrams, illustrations, and tables and 48-page color plate section, Principles and Practices of Neuro-Oncology refl ects the breadth and depth of this multi-faceted specialty.

PART I: EPIDEMIOLOGY; Section Editors: Margaret R. Wrensch MPH, PhD, Professor, Department of Neurological Surgery, University of California, San Francisco, Judith A. Schwartzbaum, PhD, Associate Professor, Divi-sion of Epidemiology, College of Public Health, The Ohio State University, and Melissa Bondy, PhD, Professor, Depart-ment of Epidemiology, Division of Cancer Prevention, The University of Texas MD Anderson Cancer Center

PART II: MOLECULAR BIOLOGY; Section Editor Abhijit Guha, Professor of Surgery (Neurosurgery), Toronto West-ern Hospital, Senior Scientist and Co-Director, The Arthur and Sonia Labatt Brain Tumour Research Centre Hospital for Sick Children, Hudson Chair in Neuro-Oncology, University of Toronto

PART III: CLINICAL PRESENTATION AND SUPPORTIVE CARE; Section Editor: Herbert B. Newton, Professor of Neurology, Neurosurgery, and Oncology, Esther Dardinger Endowed Chair in Neuro-Oncology, Department of Neuro-surgery, Dardinger Neuro-Oncology Center, The Ohio State University Medical Center, James Cancer Hospital

PART IV: NEUROANATOMY AND NEUROSURGERY; Section Editor: Michael A. Vogelbaum, Associate Director of Neurosurgical Oncology, Department of Brain Tumor and Neuro-Oncology Center, Cleveland Clinic/Neurosurgery

PART V: MEDICAL ONCOLOGY; Section Editor: Susan M. Chang, Professor, Vice Chair, Neurological Surgery Direc-tor, Division of Neuro-Oncology, University of California, San Francisco

PART VI: RADIATION THERAPY; Section Editor: Minesh P. Mehta, Professor, Department of Human Oncology, University of Wisconsin

EDITOR-IN-CHIEF: Minesh P. Mehta, MD, FASTRO, Professor, Department of Human Oncology, University of Wisconsin

EDITORS: Susan M. Chang, MD, Professor, Vice Chair of Neurological Surgery, Director, Division of Neuro-On-cology, University of California San Francisco, Abhijit Guha, MSc, MD, FRCSC, FACS, Professor of Surgery (Neurosurgery), Toronto Western Hospital, Hudson Chair in Neuro-Oncology, University of Toronto, Herbert B. Newton, MD, FAAN, Professor of Neurology, Neurosurgery, and Oncology, Esther Dardinger Endowed Chair in Neuro-

Oncology, Department of Neurosurgery, Dardinger, Neuro-Oncology Center, Ohio State Univer- sity Medical Center and Michael A. Vogelbaum, MD, PhD, FACS, The Robert and Kathryn Lamborn Chair for Neuro-Oncology, Department of Neurological Surgery, Cleveland Clinic

Neuro-oncologic (brain and spine) cancers account for 19,000 new cases and 13,000 deaths per year. The early and proper diagnosis of these virulent cancers is critical to patient out-comes and diagnosis and treatment strategies are continually evolving.

The multidisciplinary team that manages these patients involves medical and radiation oncology, neurosurgery, neuroimaging, nurses and therapists.

Principles and Practices of Neuro-Oncology establishes a new gold standard in care through a comprehensive and multidisciplinary text covering all aspects of neuro-oncology. Six major sections cover all topics related to epidemiology and etiology, clinical features and supportive care, imaging, neuroanatomy and neurosurgery, medical oncology and targeted therapies, and radiation oncology for adult and pediatric cancers. Expert contributors from multiple disciplines provide detailed and in-depth discussions of the entire fi eld of neuro-oncology including histopathologic harmonization, quality of life and therapeutic changes in terms of combined modality treatments, advanced radiation techniques, the advent of new drugs, especially targeted agents, and the tantalizing early promise of personalized thera-peutic approaches.

With contributions from over 180 authors, numerous diagrams, illustrations, and tables and 48-page color plate section, Principles and Practices of Neuro-Oncology refl ects the breadth and depth of this multi-faceted specialty.

PART I: EPIDEMIOLOGY; Section Editors: Margaret R. Wrensch MPH, PhD, Professor, Department of Neurological Surgery, University of California, San Francisco, Judith A. Schwartzbaum, PhD, Associate Professor, Divi-sion of Epidemiology, College of Public Health, The Ohio State University, and Melissa Bondy, PhD, Professor, Depart-ment of Epidemiology, Division of Cancer Prevention, The University of Texas MD Anderson Cancer Center

PART II: MOLECULAR BIOLOGY; Section Editor Abhijit Guha, Professor of Surgery (Neurosurgery), Toronto West-ern Hospital, Senior Scientist and Co-Director, The Arthur and Sonia Labatt Brain Tumour Research Centre Hospital for Sick Children, Hudson Chair in Neuro-Oncology, University of Toronto

PART III: CLINICAL PRESENTATION AND SUPPORTIVE CARE; Section Editor: Herbert B. Newton, Professor of Neurology, Neurosurgery, and Oncology, Esther Dardinger Endowed Chair in Neuro-Oncology, Department of Neuro-surgery, Dardinger Neuro-Oncology Center, The Ohio State University Medical Center, James Cancer Hospital

PART IV: NEUROANATOMY AND NEUROSURGERY; Section Editor: Michael A. Vogelbaum, Associate Director of Neurosurgical Oncology, Department of Brain Tumor and Neuro-Oncology Center, Cleveland Clinic/Neurosurgery

PART V: MEDICAL ONCOLOGY; Section Editor: Susan M. Chang, Professor, Vice Chair, Neurological Surgery Direc-tor, Division of Neuro-Oncology, University of California, San Francisco

PART VI: RADIATION THERAPY; Section Editor: Minesh P. Mehta, Professor, Department of Human Oncology, University of Wisconsin

Principles and Practice of neuro-oncologya Multidisciplinary approach to Diagnosis and Management

Recently Published Recently Published

“****4 Stars!****This is an excellent book on neuro-oncology. ...It is more comprehensive and is a better review of the current understanding of cnS tumors and their multidisciplinary management options. It is appropriate for most large academic libraries, as well as all depart-ments with a focus on neuro-oncology.”—Doody’s Reviews

handbook of Treatment Planning in radiation oncologyGregorty M.M. Videtic, MD, CM, FRCPC, Residency Program Director, and Associate Professor of Medicine, Department of Radiation Oncology, and Andrew D. Vassil, MD, Resident Physician, Department of Radiation Oncology, both of the Cleveland Clinic Foundation

Handbook of Treatment planning in Radiation Oncology is a focused pocket-sized handbook designed for Radiation Oncology trainees and residents, to serve as an up-to-date, quick resource to lead them through all of the standard steps to plan and deliver radiotherapy for all major malig-nancies.

Throughout the Handbook, the focus is on a series of steps to follow in order to successfully complete effective radiotherapy planning. Sections are organized by body site or system, whichever proved best for consistency in presenting the general principles of planning. Also included are specialized topics such as palliative therapy and pediatrics.. After a discussion of general planing requirements, each specific subsite within a given section then provides more specific details on approaches to radiotherapy planning.2010 • 260 pp • Hardcover • 978-1-933864-52-5 • E-book ISBN • 978-935281-58-0 • $75.00 / $63.75

“This is a convenient reference for residents to carry. It is also a good review for professional examinations. This book is unique in its concise and comprehensive coverage of almost all aspects of radiation therapy

planning. It can be read start to finish, but it also is useful in day-to-day practice as a quick reference.” —Doody’s Reviews

“compared with other handbooks, the book is unique since it is concise and fully covers almost all the necessary aspects. The authors wrote the book for the primary audience of oncology residents...can alsoserve as a good and quick reference for medical physics residents, dosim-etry students, therapist students, or trainees.” —Medical Physics, Volume 39, Issue 4, April 2012





1817

Malignant gliomasGuest Editors: Arnab Chakravarti, MD, Chair and Professor, Department of Radiation Oncology Max Morehouse Chair of Cancer Research, Co-Direc-tor, Brain Tumor Program, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University Medical School and Martin Fuss, MD, Professor and Vice Chair, Director Program in Image-guided Radiation Therapy, Department of Radiation Medicine, Oregon Health & Science University

Malignant Gliomas provides a multidisciplinary update on the treatment of the complex area of malignant gliomas. Authoritative reviews and updates discuss recent advances in radiation therapy including coverage of emerging areas such as BNCT, proton therapy and brachyther-apy applications in malignant glioma treatment. In addition, reviews of current developments in advanced and metabolic imaging, neuropathology, surgical approaches, anti-angiogenesis, kinase inhibitors, biomarkers and genetic therapy are included. This volume of Radiation Medicine Rounds will give the radiation oncology professional a complete overview of current best practices and emerging modalities for treatment of these difficult tumors.conTenTS: 1. Overview; 2. Surgical Approaches and Recent Advances; 3. Radiation Oncology Approaches and Recent Advances; 4. Advanced Imaging’ 5. Metabolic Imaging; 6. BNCT (Boron Neutron Capture Therapy); 7. Neuropathology; 8. Anti-Angiogenesis; 9. Kinase Inhibitors; 10. Gene Therapy; 11. Immunotherapy; 12. Proton/Brachytherapy; 13. Biomarkers

September 2012 • 200 pp. • Hardcover • ISBN13 978-1-936287-78-9 E-book ISBN 978-1-617051-31-9 • $85.00/$72.25

breast cancerGuest Editor: Alphonse Taghian, MD, Associate Professor of Radiation Oncology, Massachusetts General Hospital, Boston, MA and Michele Y. Halyard, MD, Associate Professor of Oncology , Department of Radiation Oncology, Mayo Clinic - Scottsdale, AZ

This issue of Radiation Medicine Rounds discusses the more salient topics surrounding the role of radiation therapy in breast cancer. The specialty of radiation therapy has increased in complexity over the years, yet as technology improves, the goal of improving outcomes while decreas-ing toxicity remains critical. Breast Cancer provides the practitioner with a full current overview of the present best practices and recent research in management of this complex and challenging cancer.conTenTS: 1. History of Radiation Therapy for Breast Cancer, 2. Role of Radiation Therapy in DCIS, 3. Advances in Accelerated Partial Breast Irradiation, 4. Hypofractionation for Breast Cancer, 5. Post Mastectomy RT, 6. RT after Neo-adjuvant Chemotherapy, 7. Radiotherapy and Breast Reconstruction, 8. Local Failure and Biological Subtypes, 9. The use of IMRT in Breast Cancer, 10. Role of Protons in Breast Cancer, 11. Cardiac Exposure to Radiation, 12. Individual-izing Risk of Loco-Regional Recurrence with Molecular and Genomic Classifiers, 13. Current and Future State of Breast Radiation Therapy April 2012 • 192 pp. • Hardcover • 978-1-936287-65-9 • E-book ISBN 978-1-617050-43-5 • $85.00 / $72.25

gynecologic cancerArno J. Mundt, MD, Professor and Chair, Department of Radiation Oncology, Catheryn Yashar, MD, Associate Professor, Chief of Breast and Gynecologic Radiation Services, Director of Medical School Education, De-partment of Radiation Oncology, Loren Mell, MD, Assistant Professor of Radiation Oncology, Department of Radiation Oncology, all of University of California, San Diego

With contributions from experts across the U.S., Gynecologic Cancer details the current management of different types of gynecologic cancer. Today the management of gynecologic cancers is multidisciplinary in nature, requiring close collaboration between gynecologic oncologists, medical oncologists, and radiation oncologists. Gynecologic Cancer reviews new therapies in use and under development for gynecologic cancer including novel radiation approaches, the role of chemotherapy and novel biologic agents, new and emerging surgical approaches, and the role of MRI in assessing tumor response in cervical cancer patients.

December 2011 • 200 pp Hardcover 978-1-936287-47-5 • E-book ISBN 9781617050954 $85.00 / $72.25

A New Cutting-Edge Review Publication in Radiation Medicine

EDITOR-IN-CHIEF: Charles R. Thomas, Jr., MD, Professor and Chairman, Depart-ment of Radiation Medicine, and Professor of Hematology/Oncology, Knight Cancer Insti-tute, Oregon Health Sciences University

FEATURES OF RADIATION MEDICINE ROUNDS INCLUDE:

In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Radiation Medicine

Each issue edited by an authority in that subject area

Each issue focused on a single major topic in Radiation Medicine, providing coverage of advances in radiation science, radiation medicine technology, radiation medicine practice, and assessment of recent quality and outcome studies

Radiation Medicine Rounds is available by subscription and individual issues. Individual subscriptions include print issue for volume year subscribed to and onlineaccess to all back issues.

North American Individual Subscription Rate: $199.00 / $161.50 International Individual Subscription Rate: $225.00 / $191.25

Published three times a year Radiation Medicine Rounds provides authoritative, thorough assessments of a wide range of “hot topics” and emerging new data for the entire specialty of radiation medicine.

hematologic MalignanciesGuest Editors: Michael Tomblyn, MD, MS Assistant Member Radiation Oncology Moffitt Cancer Center & Research Institute, Tampa FL; Karen Winkfield, MD, PhD, Hematologic Malignan-cy Service, Department of Radiation Oncology, Massachusetts General Hospital; Bouthaina S. Dabaja, MD, Associate Professor, Depart-ment of Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Authoritative reviews and updates discuss recent advances in radiation therapy in treatment of Hodgkins lymphoma, B-cell nodal and extranodal lymphomas, follicular lymphoma and cutaneous T-cell lymphoma; mantle cell lymphoma, and leukemia. In addition, reviews of current developments in PET imaging in lymphoma, radioimmunotherapy, and radiation and transplant, are included. This volume of Radiation Medicine Rounds gives the radiation oncology professional a complete overview of current best practice and emerging modalities for radiation treatment of hematologic malignancies.conTenTS: 1. Hodgkin’s early and advanced; 2. Diffuse Large B cell nodal and extranodal; 3. Follicular lymphoma; 4. Marginal zone lymphoma; 5. Cutaneous T cell lymphoma; 6. NK cell lymphoma; 7. Mantle cell lymphoma and other ag-gressive lymphomas; 8. Leukemia including lymphomblastic lymphoma; 9. Plasma cell dyscrasias; 10. PET in lymphoma; 11.Radioimmunotherapy; 12. Radiation and transplant

December 2012 • 224 pp. • Hardcover • 978-1-936287-77-2 • E-book ISBN 978-1-617051-49-4 • $85.00 / $72.25

Radiation Medicine RoundsEditor-in-Chief: Charles R. Thomas, Jr. RMR

Editor-in-Chief: Charles R. Thomas, Jr. Radiation Medicine Rounds RMR

Head and neck cancerDwight E. Heron, MD, Guest Editor

Roy B. Tishler, MD, PhD, Guest Editor

Radiation Medicine Rounds is a trinary, hard cover, periodical designed to provide an up-to-date review of a dedicated radiation medicine topic of interest to clinicians and scientists who are involved in the care of patients receiving radiotherapy. It is intended to serve as both a reference and instructional tool for students, housestaff, fellows, practicing clinicians, medical physicists, cancer biologists, radiobiologists, and interdisciplinary colleagues throughout the oncology spectrum. This issue of Radiation Medicine Rounds addresses a wide range of topics under the broad heading of head and neck oncology. In the initial section, the authors address therapeutic approaches with chapters on current and future treatments. Coverage is extensive and includes articles on IMRT, combined modality treatments, the use of targeted agents in conjunction with chemotherapy, the use of transoral robotic surgery followed by postoperative radiation therapy, and the use of particle therapy. The second section addresses issues of health services and covers palliative care, how to assess toxicity in patients, and issues of interpreting and integrating classic study data into treatment decisions. The third section examines factors influencing clinical decisions including biomarkers and image guidance.

Included in Head and Neck Cancer I. Therapeutic Approaches •Intensity-ModulatedRadiationTherapyforHeadandNeckCancer:ADecadeofExperience

Demonstrates Improved Patient Outcomes •ConcurrentChemotherapyandRadiationforHeadandNeckCancer •TargetedTherapyforSquamousCellCarcinomaoftheHeadandNeck •InductionChemotherapyinHeadandNeckCancer:AStandardofCare •PostoperativeManagementFollowingTransoralRoboticSurgeryforOropharyngealCarcinomas •ParticleTherapyinTreatmentofHeadandNeckCancer •OptimizingTreatmentStrategiesinRecurrentHeadandNeckCancers

II. Health Services in Head and Neck Cancer •OutcomesResearchinHeadandNeckCancer •PalliativeCareandSymptomManagementintheHeadandNeckCancerPatient •ToxicityAssessmentandReportinginRadiotherapyofHeadandNeckCancer

III. Factors Influencing Clinical Decisions •BiomarkersandMolecular-TargetedTherapeuticsinSquamousCellCarcinomaofthe

HeadandNeck •Image-GuidanceintheRadiotherapeuticManagementofHeadandNeckCancer:

CurrentStrategiesandOngoingChallenges

11W.42ndStreetNewYork,NY10036www.demosmedpub.com

Recommended ShelvingCategory:Oncology

Cover design by Joe Tenerelli

Volume 2 • Issue 2 • 2011

CoverImagecourtesyofSteveRhodes,BS,RT(T),CMDandDebraMonaco,RT(R)(T),CMD

RMR

Radiation Medicine Rounds

2011 2:2

Hematologic Malignancies

Hem

atolo

gic

Malig

nan

cies

Michael Tomblyn • Karen Winkfield Bouthaina S. Dabaia

Tom

blyn • W

inkfield • D

abaia

Malignant glioMas

Arnab ChakravartiMartin Fuss

G U E S T E D I T O R S

Radiation Medicine RoundsSeries Editor: Charles R. Thomas, Jr. RMR

radiation Medicine rounds

radiation Medicine roundsEDITOR-IN-CHIEF: Charles R. Thomas, Jr., MD, Professor and Chairman, Department of Radiation Medicine, and Professor of Hematology/ Oncology, Knight Cancer Institute, Oregon Health Sciences University

Published three times a year Radiation Medicine Rounds provides authoritative, thorough assessments of a wide range of “hot topics” and emerging new data for the entire specialty of radiation medicine. Radiation Medicine Rounds is a valuable tool for clinicians, nurses, researchers, medical students, residents, and fellows.

FEATURES OF RADIATION MEDICINE INCLUDE:

r In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Radiation Medicine

r Each issue edited by an authority in that subject area

r Each issue focused on a single major topic in Radiation Medicine, providing coverage of advances in radiation science, radiation medicine technology, radiation medicine practice, and assessment of recent quality and outcome studies.

ForThcoMIng DeceMber 2012





2019

Proton TherapyGuest Editor: James M. Metz, MD, Associate Professor and Vice Chair, Clinical Division, Radiation Oncology, Hospital of the University of Pennsylvania

“This well-composed collection of papers certainly will give readers with useful information about proton therapy — the past, present, and future.”—Doody’s Reviews

2010 • 200 pp • Hardcover • 978-1-936287-15-4 E-book ISBN • 978-1-617050-44-2 $89.00 / $75.65

lower gastrointestinal MalignanciesGuest Editors: Edgar Ben-Josef, MD, Associate Professor, Depart-ment of Radiation Oncology, University of Michigan Medical Center, and Albert Koong, MD, PhD, Assistant Professor, Department of Radiation Oncology, Stanford University

Includes chapters on the evolution of systemic agents, neoadjuvant treatment, radiation therapy, chemoradiation therapy, rectal cancer and anal cancer covering the vast majority of these tumors. The multidisciplinary nature of the articles provides readers with an up-to-date summary and a well-rounded review regarding these tumors and their care.

2010 • 184 pp • Hardcover • 978-1-933864-92-1 E-book ISBN • 978-1-935281-46-7 • $89.00 / $75.65

Thoracic MalignanciesGuest Editor: Steven E. Schild, MD, Professor and Chairman, De-partment of Radiation Oncology, Mayo Clinic, Scottsdale

Included are chapters on lung cancer, esophageal cancer, and thymomas providing coverage of the vast majority of thoracic tumors. The multidisciplinary nature of the articles provides readers with an up-to-date summary and a well-rounded review regarding these tumors and their care.

2010 • 248 pp • Hardcover 978-1-933864-89-1 E-book ISBN • 978-1-935281-80-1 • $89.00 / $75.65

head and neck cancerGuest Editors: Dwight E. Heron, MD, FACRO, Associate Professor of Radiation Oncology at the University of Pittsburgh School of Medicine, and Roy B. Tishler, MD, PhD, Associate Professor of Radiation Oncology, Harvard Medical School

This volume of Radiation Medicine Rounds examines the latest advances in the use of radiation medicine in treatment of head and neck cancer. Head and neck cancer treatment has undergone major change over the course of the past few years and Head and Neck Cancer addresses current best practices in the light of the most recent evidence. All of the chapters are written by international experts in the field,

address the common clinical scenarios in head and neck cancer and are multidisciplinary in scope. Chapters examining health services in head and neck cancer as well as factors influenc-ing clinical decisions round out the coverage.

2011 • 172 pp • Hardback • 978-1-936287-36-9 • E-book ISBN • 978-1-617050-71-8 • $85.00 / $72.25

Prostate cancerGuest Editors: Allen M. Chen, MD, Assistant Professor and Director, Residency and Fellowship Training Program, Department of Radiation Oncology, UC Davis Medical Center, and Srinivasan Vijayakumar, MD, DMRT, FACR, Department Chair and Professor, Department of Radiation Oncology, University of Mississippi Medical Center

Prostate cancer is the most common cancer in males and radiation therapy is a major tool in the management of the disease. prostate Cancer includes reviews of all major recent advances in treatment of favorable, intermediate and high-risk prostate cancer as well as newer modalities such as brachytherapy, stereotactic body radiation therapy, and proton beam radiotherapy. Articles also review current knowledge in the areas of new biomarkers, risk stratification, and risk stratification. This volume provides the practitioner with a full current overview of the present best practices and recent research in management of this complex and challenging disease.


“This well-composed collection of papers certainly will give readers with useful information about proton therapy -- the past, present, and future.” —Doody’s Reviews

radiation Medicine rounds





2221

Recently Published in Oncology

biliary Tract and gallbladder cancerDiagnosis and Therapy Charles R Thomas, Jr, MD, Professor and Chairman of the Department of Radiation Medicine, Oregon Health & Science University, Clifton David Fuller, MD, Department of Radiation Oncology, The University of Texas Health Science Center at San Antonio

Biliary Tract and Gallbladder Cancer: Diagnosis and Therapy is a comprehensive and de-finitive discussion of all aspects of the treatment of malignant tumors of the gallbladder and biliary tract. This is the first book to examine these cancers in such depth, as rapid advances in surgical oncology and radiotherapeutic approaches have demanded the full coverage this text provides. 2008 • 296 pp • Hardback • 978-1-933864-42-6 • E-book ISBN • 978-1-935281-23-8 • $165.00 / $140.25

brain Metastasisa Multidisciplinary approach Lawrence R. Kleinberg, MD, Associate Professor of Radiation Oncology, The Johns Hopkins University School of Medicine

Brain Metastasis: A Multidisciplinary Approach conveys vital information about management strategies, outcomes, and techniques to enable oncologists to provide a full range of appropriate care and counseling to patients with meta-static spread to the brain.

Brain Metastasis includes complete discussions for all situations in which radiosurgery might be recommended, including for the treatment of gross brain metastasis, for the prevention of tumor-related injury of brain function, and as an alternative to whole-brain radiotherapy.


combining Targeted biological Agents with radiotherapycurrent Status and future Directions William Small, Jr, MD, Professor of Radiation Oncology and Vice-Chairman of the Department of Radiation Oncology, Northwestern University

Combining Targeted Biological Agents with Radiotherapy: Current Status and Future Directions is an overview of the current state of clinical and pre-clinical research in combining radiotherapy with targeted biological agents to fight cancer. The text provides a general overview of targeted agents, reviews the current clinical trials, and includes a look at the future of this state-of-the-art practice.


Synopsis of clinical oncologyMichael D. Stubblefield, MD, Assistant Professor of Rehabilitation Medicine, Weill Medical College of Cornell, University Rehabilitation Medicine Service, Memorial Sloan-Kettering Cancer Center and Michael O’Dell, MD, Chief of Clinical Services, Department of Rehabilitation Medicine New York Presbyte-rian Hospital/Weill Cornell Medical Center, Professor of Clinical Rehabilitation Medicine, Weill Cornell Medical College


“...an excellent choice for any physician seeking a comprehensive, multidisciplinary, and cutting-edge review of biliary tract and gallbladder cancer.” — Uzma D. Siddiqui, MD, Journal of clinical gastroenterology, volume 43, number 9, october 2009

“This is an excellent resource. It is well written and tightly edited. It should be in every large insti-tutional resource library and would be an invaluable tool for medical and surgical oncology fellows and radiation oncology residents.”—Doody’s Reviews

“...comprehensive reviews of current studies and planned studies... well- written.” —Doody’s Reviews

Recently Published in Oncology

oncology clinical TrialsSuccesful Design, conduct, and analysis William Kevin Kelly, DO, Professor of Medical Oncology, Jefferson Medical College, and Susan Halabi, PhD, Associate Professor, Department of Biosta-tistics and Bioinformatics, Duke University Medical Center

Oncology Clinical Trials provides a comprehensive guide for both early-career and senior oncology investigators into the successful design, conduct and analysis of an oncology clinical trial. Oncology Clinical Trials covers how to formulate a study question, selecting a study population, study design of Phase I, II, and III trials, toxicity monitoring, data analysis and reporting, use of genomics, cost-effectiveness analysis, systemic review and meta-analysis, and many other issues. Many examples of real-life flaws in clinical trials that have been reported in the literature are included throughout. 2010 • 448 pp • Hardcover • 978-1-933864-38-9 • E-book ISBN • 978-1-935281-76-4 • $130.00 / $110.50

esophageal cancerPrinciples and PracticeBlair A. Jobe, MD, Associate Professor of Surgery, University of Pittsburgh Medical Center, Charles R. Thomas, Jr., MD, Professor and Chairman of the Department of Radiation Medicine, Professor of Hematology/ Oncology, Knight Cancer Institute, Oregon Health Sciences University, John G. Hunter, MD, Chairman of the Department Of Surgery at Oregon Health Sciences University


cancer rehabilitationPrinciples and PracticeMichael D. Stubblefield, MD, Assistant Professor of Rehabilitation Medicine, Weill Medical College of Cornell, University Rehabilitation Medicine Service, Memorial Sloan-Kettering Cancer Center and Michael O’Dell, MD, Chief of Clinical Services, Department of Rehabilitation Medicine New York-Presbyterian Hospital/Weill Cornell Medical Center. Professor of Clinical Rehabilitation Medicine, Weill Cornell Medical College

2010 • 1,092 pp • Hardcover • 978-1-933864-33-4 • E-book ISBN • 978-1-935281-38-2 • $199.00 / $169.15

“This is an easy read for beginners struggling to understand the complicated discipline of oncology. In comparison to other books on oncology, this one is unique in its focus on pro-fessionals not familiar with the field.” —Doody’s Reviews

“It is a single, comprehensive source for current information regarding the biology, staging, and treatment of esophageal cancer, as well as an excellent guide to the management of patients suffering from this disease.” —International Journal of Radiation Oncology Biology and Physics, Vol. 75, no. 5

“It is truly a well-written, practical, comprehensive text. It should serve as a helpful, handy reference to anyone involved in the treatment of this disease.” —Gastrointestinal Cancer Research, January/February 2011, Volume 4, Issue 1

“This book is a must-have for clinicians who wish to specialize in cancer rehabilitation.” —Doody’s Reviews

“This book is a milestone and must-have for anyone involved in the care of those with cancer.“ —American Journal of Physical Medicine and Rehabilitation

”...excellent accounts of cancer syndromes causing physical disability and pain, and well-done matched chapters that describe wider therapeutic approaches to help patients with these syndromes.” —International Journal of Radiation Oncology, Biology, and Physiology, Vol. 77, no. 5

A DooDY’S core TITle

2012





2423

Of Related Interest to Oncologists

The Demos Surgical Pathology Guides Series Provides High-Yield Diagnostic Summary and Review in Surgical Pathology

Demos Surgical Pathology guidesEditor-in-Chief: Saul Suster, MD, Professor and Chairman, Department of Pathology and Labo-ratory Medicine, Medical College of Wisconsin

The Demos Surgical pathology Guides Series presents in summary and visual form the basic knowledge base practicing pathologists need. Series volumes cover the major specialty areas of surgical pathology, and coverage emphasizes key entities and diagnoses. Emphasis is on basic morphology with newer techniques represented where they are frequently used. An additional feature is the “expert tips” from experienced diagnosticians. The series provides a handy summary and quick reference. Experienced practitioners will find the series valuable as a portable “refresher course” or review tool.

lymph nodesSteven H. Kroft, MD, Professor of Pathology; Vice Chair of Clinical Pathology; Director of Hematopathology; Residency Program Director, Medical College of Wisconsin; Alexandra Harrington, MD, MT, Assistant Professor of Pathology, Medical College of Wisconsin; Director of Coagulation, Dynacare Laboratories, and Horatiu Olteanu, MD, PhD, Assistant Professor of Pathology, Medical College of Wisconsin; Program Director, Hematopathology Fellowship; Director of Flow Cytometry, Dynacare Laboratories

Lymph Nodes presents the full gamut of key lymph nodes disorder entities and diagnoses that a practitioner can expect to encounter in daily practice.

October 2012 • 208 pp. • Softcover • 978-1-936287-08-6 • E-book ISBN 978-1-617050-20-6 • $75.00/$63.75

Inflammatory Skin DisordersJose A. Plaza, MD, Assistant Professor of Pathology, Director of Dermatopa-thology, Department of Pathology, Medical College of Wisconsin and Victor G. Prieto, MD, PhD, Professor of Pathology and Dermatology, Section Chief, Dermatopathology, Department of Pathology, MD Anderson Cancer Center

Inflammatory Skin Disorders, the third volume in the Demos Surgical pathology Guides Series provides essential information on a range of key in-flammatory skin diagnoses, including but not limited to those that pathologists commonly see in daily practice

January 2012 • 274 pp. • Softcover • 978-1-933864-87-7 E-book ISBN 978-1-935281-96-2 • $75.00 / $63.75

breast PathologyGiovanni Falconieri, MD, Department of Pathology General University Hospital, Udine, Italy, Janez Lamovec, MD, Professor of Pathology, Department of Pathology, Institute of Oncology, Ljubljana, Slovenia, and Abiy B. Ambaye, MD, Associate Professor, Department of Pathology, University of Vermont

Breast Pathology provides essential information on a range of key breast entities and diagnoses. Traditional morphology, coupled with clinical data, is emphasized, and each chapter is complemented with as many photographs as possible, including macroscopic images.

October 2011 • 200 pp. • Softcover • 978-1-936287-30-7 • E-book ISBN 978-1-617050-60-2 • $75.00 / $63.75

head and neck PathologyPaul E. Wakely, MD, Professor of Pathology, Department of Pathology, The Ohio State University Medical Center

Head and Neck pathology concentrates on the salient H&E histopathology of each entity discussed with brief descriptors of the clinical features, differential diagnosis, and relevant literature references for each entity. The book features a bulleted format with H&E illustrations to match histopathologic criteria.

2011 • 208 pp. • Softcover • 978-1-933864-84-6 E-book ISBN 978-1-617050-24-4 • $75.00 / $63.75

ForThcoMIng ocTober 2012

Of Related Interest to Oncologists

effusion cytologya Practical guide to cancer DiagnosisParvin Ganjei-Azar, MD, Professor of Pathology, Director of Cytology Labo-ratories, Jackson Memorial Health System, Sylvester Comprehensive Cancer Center, Director of the Cytopathology Fellowship Program, Department of Pathology, Miller School of Medicine, University of Miami, Miami, Florida, Mercè Jordà, PhD, Professor of Pathology, Department of Pathology, Miller School of Medicine, University of Miami, Director of Laboratory Services, Sylvester Comprehensive Cancer Center, University of Miami Hospitals,

Miami, Florida, Awtar Krishan, PhD, Professor of Pathology, Department of Pathology, Miller School of Medicine, University of Miami, Miami, Florida

Effusion Cytology is a practical manual in diagnosis and interpretation of body cavity fluid (BCF) specimens. This highly illustrated volume provides handy information for residents, fellows, and general pathologists with a step-by-step guide to evaluation of BCF specimens with the specific goal of identification of malignancies. Use of ancillary techniques such as immunocy-tochemistry is discussed where appropriate. Special attention is given to the formulation of final cytologic reports of the diagnosis of difficult cases.2011 • 192 pp • Softcover • 978-1-933864-65-5 • E-book ISBN • 978-1-935281-41-2 • $85.00 / $72.25

brain TumorsConsultant Pathology SeriesRichard Prayson, MD, Section Head for Neuropathology at Cleveland Clinic Main Campus, Cleveland, OH, Bette Kleinschmidt-DeMasters, MD, Head of Neuropathology at the University of Colorado, Denver, and Professor of Pathology at the University of Colorado, Denver School of Medicine, Mark Cohen, MD, Director of the Division of Neuropathology, University of Cleveland and Professor of Pathology, Case Western Reserve University, School of Medicine

Surgical neuropathology is a challenging arena for many pathologists, due in large part to a relative lack of experience of most pathologists in this area compared to other areas of surgical pathology. Brain Tumors is intended to address this need with cases drawn from the surgical neuropathology practices of the authors.

This volume provides examples of over 100 brain tumors, running the gamut from the very common to the rare. Each example is presented in a case based format and the wide variety of cases presented covers the entire scope of brain tumors and offers the opportunity to review both the basics for the beginner or relatively inexperienced pathologist and also offers experienced pathologists the chance to see some of the rare entities.2010 • 318 pp • Hardcover • 978-1-933864-69-3 • E-book ISBN • 978-1-935281-36-8 • $145.00 / $123.25

Metastatic carcinomas of unknown originMark R. Wick, MD, Professor of Pathology, University of Virginia Health System

Metastatic Carcinomas of Unknown Origin is the first comprehensive, fully illustrated discussion of the clinical features, pathologic attributes, and treatment approaches of metastatic carcinomas of unknown origin (MCUOs). This unique text provides a framework for approaching these complex issues, with contributions from international experts in the field of MCUOs.


“...Truly a practical guide to cancer diagnosis from effusion cytopathological examination. get this book if your main job is cytopathology or cytotechnology. It doesn’t get much more concise, clear, and definitive than this.”—Doody’s Reviews

“…this is a unique and concise textbook that incorporates a framework for how to approach metastatic carcinomas of unknown origin. It covers the spectrum of presentation of these lesions through treatment and postmortem validation.” —The ASC Bulletin, Volume XLVII, Number 6, November 2010

US cUSToMeRS Receive fRee ShiPPiNg*WheN YoU oRDeR oNliNe *oN oRDeRS oveR $29.00

Use Discount Code ONC 2012 when ordering online Save 15%

Please send me: Title

• Add $7.50 for the �rst book; $2.50 for each additional book

for standard UPS shipping within North AmericaFor international orders in the UK, Europe, Middle East, Australia and New Zealand please contact customer service at [email protected] Call 1-800-532-8663 for expidiated shipping rates

•

•

Send to: 11 West 42nd Street, New York, NY 10036 Phone: 212.683.0072 Fax: 212.941.7842

ISBN Quantity

Subtotal

Tax

Shipping

Total

Price

www. demosmedpub.com

*on orders more than $29.00

Prices subject to change without notice

Order Con�rmation

Enclosed is a check or money order in full payment.(Make all checks payable to DEMOS. Payment must be made in U.S. dollars drawn on a U.S. bank)

Charge my account

Method of Payment

VISA MC AMEX Discover

Residence or Business Please complete the shipping information below

DEMOS MEDICAL PUBLISHING

Many Demos Medical Titles are Now available in E-book format.

to �nd your favorite Demos titles in a variety of formats.

Visit Amazon, bn.com, and Google Books

Save 15% Plus Free ShippingWhen You Order Online

USE DISCOUNT CODE ONC 2012

Name (please print)

Signature

Card Number Exp. Date

Email for con�rmation of order

Country Telephone Fax

Address

City State Zip

A�liation Department

New York residents add appropriate sales taxTotal amount payable

Please send me the books indicated Total OrderShipping / Handling

Free Shipping and Discounts apply only to orders shipped within the United States

orDer ForM

To oRDeR viSiT www.demosmedpub.com

Documents

oncologY 2012 · Manual of Cancer Treatment Recovery presents the first comprehensive program to guide the recovery from cancer and its treatment. ... healing right from the start,